A Pharmacokinetic/Pharmacodynamic Perspective on the Effect of Bruton's Tyrosine Kinase Inhibitors on Collagen-Induced Platelet Aggregation

Bruton's tyrosine kinase (BTK) and TEC may perform redundant functions in collagen-induced platelet (PLT) aggregation. Ibrutinib (ibr), a first-in-class, once-daily inhibitor of BTK, is indicated for the treatment of patients with B-cell malignancies and allows for treatment without chemotherapy. Clinical trials on ibr and other BTK inhibitors (BTKis), including ONO-4059 and ACP-196, identified bleeding as an adverse event, but whether bleeding is from inhibition of BTK or both BTK and TEC remains unclear.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research